Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

J Clin Pharmacol · 2025 · PMC12555096 · PMID 40641008

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Bone marrow plasma cell (%) data were missing in >10% of subjects, excluding it from analysis, though its correlation with AUC0‐28D suggested a positive trend (Figure S16 ).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.